A
Andrew N. Phillips
Researcher at University College London
Publications - 837
Citations - 60429
Andrew N. Phillips is an academic researcher from University College London. The author has contributed to research in topics: Viral load & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 108, co-authored 776 publications receiving 55705 citations. Previous affiliations of Andrew N. Phillips include Birmingham City Hospital & University of California, Santa Cruz.
Papers
More filters
Journal ArticleDOI
Meta-analysis: Principles and procedures
TL;DR: These principles are discussed, along with the practical steps in performing meta-analysis, which allow a more objective appraisal of the evidence than traditional narrative reviews, provide a more precise estimate of a treatment effect, and may explain heterogeneity between the results of individual studies.
Journal ArticleDOI
CD4+ count-guided interruption of antiretroviral treatment.
Wafaa El-Sadr,Wafaa El-Sadr,Jens D Lundgren,James D. Neaton,Fred M. Gordin,Dominic Abrams,Roberto C. Arduino,Abdel Babiker,William J. Burman,Nathan Clumeck,Calvin J. Cohen,David V. Cohn,David A. Cooper,Janet Darbyshire,Sean Emery,Gerd Fätkenheuer,Brian Gazzard,Birgit Grund,Jennifer F Hoy,Karin L. Klingman,M. H. Losso,Norman Markowitz,Jacquie Neuhaus,Andrew N. Phillips,Claire Rappoport +24 more
TL;DR: Episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antireteviral therapy, largely as a consequence of lowering theCD4+ cell count and increasing the viral load.
Journal ArticleDOI
Combination antiretroviral therapy and the risk of myocardial infarction
Nina Friis-Møller,Caroline A. Sabin,Rainer Weber,Antonella d'Arminio Monforte,Wafaa El-Sadr,Peter Reiss,Rodolphe Thiébaut,Linda Morfeldt,Stéphane De Wit,Christian Pradier,Gonzalo Calvo,Matthew Law,Ole Kirk,Andrew N. Phillips,Jens D Lundgren +14 more
TL;DR: Combination antiretroviral therapy was independently associated with a 26 percent relative increase in the rate of myocardial infarction per year of exposure during the first four to six years of use, however, the absolute risk of my Cardiac Infarction was low and must be balanced against the marked benefits from antireTroviral treatment.
Journal ArticleDOI
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Matthias Egger,Margaret T May,Geneviève Chêne,Andrew N. Phillips,Bruno Ledergerber,François Dabis,Dominique Costagliola,Antonella d'Arminio Monforte,Frank de Wolf,Peter Reiss,Jens D Lundgren,Amy C. Justice,Schlomo Staszewski,Catherine Leport,Robert S. Hogg,Caroline A. Sabin,M. John Gill,Bernd Salzberger,Jonathan A C Sterne +18 more
TL;DR: The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines.
Journal ArticleDOI
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
Sheena McCormack,David Dunn,Monica Desai,David Dolling,Mitzy Gafos,Richard Gilson,Richard Gilson,Ann Sullivan,Amanda Clarke,Iain Reeves,Gabriel Schembri,Nicola Mackie,Christine Bowman,Charles J.N. Lacey,Vanessa Apea,Michael Brady,Julie Fox,Stephen Taylor,Simone Antonucci,Saye Khoo,James F. Rooney,Anthony Nardone,Martin Fisher,Alan McOwan,Andrew N. Phillips,Anne M Johnson,Brian Gazzard,ON Gill +27 more
TL;DR: In this high incidence population, daily tenofovir–emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting.